Tryptamine

Urinary tryptamine has been studied in Parkinson's disease, autism, and kidney transplant tolerance. Those studies are exploratory. They haven't established this measurement as a way to predict disease, assess brain chemistry, or choose a treatment.

There are no established clinical decision thresholds or proven health benefits from tracking this marker. A laboratory can measure a compound accurately while its medical interpretation remains uncertain. That's the distinction that matters for this test.

What It Is and Where It Comes From

Tryptophan is one of the building blocks of protein that you need to get from food. Your body uses it to build proteins and make other compounds. A chemical reaction that removes a small group from tryptophan produces tryptamine. Human tissues can perform this reaction, and researchers have identified gut bacterial strains that can do it too.

Monoamine oxidase helps break tryptamine down. Some tryptamine leaves your body unchanged in urine. The amount in a sample therefore depends on production, breakdown, and excretion; it doesn't identify how much came from your brain or from particular gut bacteria.

Other routes turn tryptophan into serotonin and compounds in the kynurenine pathway. These routes share starting material, but a urinary tryptamine result cannot show what proportion of your tryptophan went through each one.

What the Experimental Biology Shows

Research in mice and mouse intestinal cell cultures shows that bacteria-derived tryptamine can activate a serotonin receptor in the gut lining, increase fluid secretion, and speed intestinal movement. This provides a biological reason to study the compound. It doesn't establish that your urine level measures bowel function or explains digestive symptoms.

What This Urine Measurement Means

This assay uses liquid chromatography-mass spectrometry, abbreviated LC-MS. It separates compounds in the sample and detects characteristic mass signals to identify and quantify tryptamine. The catalog reports results in mcg/g. The laboratory report needs to specify what the gram denominator represents before the number can be compared with another result.

Studies have used different collection procedures, analytical methods, and ways of adjusting for urine concentration. Some report concentrations per volume, others adjust to creatinine, and others compare relative instrument signals. Their numerical results aren't automatically interchangeable with this assay.

Parkinson's Disease

A 2023 study measured tryptophan-related compounds in urine using LC-MS/MS and found no statistically significant difference in tryptamine between people with Parkinson's disease and controls. Indole-3-acetic acid emerged as a candidate marker in that study, but it is a different molecule.

A separate study found differences in circulating trace amines between newly diagnosed and treated Parkinson's groups. That study measured plasma from blood samples. Its findings don't establish an interpretation for urinary tryptamine, and comparisons between treatment groups cannot cleanly separate medication effects from differences in the disease.

These studies examined people who already had Parkinson's disease. They do not establish that urinary tryptamine predicts Parkinson's before symptoms, including when the disease runs in your family.

Autism in Children

A 2026 study compared urinary tryptophan compounds in children with and without autism, including an age- and sex-matched analysis. Creatinine-adjusted urinary tryptamine tended to be higher in the autism group, but the difference was not statistically significant. This is a single cross-sectional study and has not been replicated.

The study also reported positive associations between urinary tryptamine and urinary magnesium, zinc, and selenium. These measurements describe compounds excreted together. They don't establish a nutrient deficiency, show that mineral supplements would help, or validate tryptamine as an autism test. Diet, medication, and supplement use can also shift urinary tryptophan compounds, which limits interpretation.

Kidney Transplant Tolerance

A small study found higher urinary tryptamine and kynurenic acid in selected kidney transplant recipients with spontaneous operational tolerance. These recipients maintained functioning transplants without immunosuppressive treatment. The researchers compared relative metabolite signals using study-specific sample preparation and normalization, so the findings can't be converted into a target for this mcg/g assay.

The association doesn't show that increasing tryptamine causes tolerance or that a urine result can identify who can safely stop anti-rejection medicines. Decisions about those medicines require your transplant team's assessment.

When Results Can Be Misleading

• Medicines: human studies found that monoamine oxidase inhibitors can increase urinary tryptamine by slowing its breakdown. This is a medication effect, not evidence that the conditions being investigated in biomarker studies have developed. The older research does not establish the expected size of the change on this LC-MS assay.
• Tryptophan supplements and collection timing: older human studies using fluorescence-based measurements found short-term increases after oral tryptophan and variation across the day. They don't establish how much an ordinary meal changes this test or how large a change between repeat LC-MS results is medically meaningful.
• Urine acidity: an older human study found that urinary tryptamine excretion depended on urine pH. The size of this effect under the current assay's collection conditions has not been established.
• Urine concentration and normalization: if the laboratory reports tryptamine relative to creatinine, both measurements affect the ratio. Creatinine adjustment is intended to account for urine dilution, but creatinine excretion also varies with muscle mass and kidney function. This is a general limitation of creatinine-adjusted urine measurements.
• LC-MS limitations: other chemicals in urine can weaken or enhance the instrument signal. Incomplete separation, sample preparation losses, and calibration differences can also affect results. Laboratories need to evaluate and control these effects for their own assay.
• Sample handling: stability depends on the collection container, preparation, storage temperature, and handling time. Refrigeration or a freeze-thaw cycle does not automatically invalidate a result; stability must be established for the particular procedure.